Network biology meets
drug discovery
We engineer medicine based not on a single target, but the biological network as a whole.
+250k
Chemotranscriptomes
Generated
Generated
+2.3B
mRNAs Measured
3
Drug Programs in
the Pipeline
the Pipeline
Our Technology
Chemotranscriptomes
Arpeggio is developing the world's fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology.
Our Pipeline
Chronic disease
99.5% of adults over fifty will have a chronic disease by 2040. We're working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration.
Featured news
Kevin Eastwood Joins as Chief Business Officer
Arpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.
Kevin Eastwood Joins as Chief Business Officer
Arpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.
Arpeggio Raises $17M in Series A
We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
Arpeggio Raises $17M in Series A
We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
Arpeggio at AACR 2024
Arpeggio presented two exciting posters sharing updates on our GPX4 inhibitor and announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.
Arpeggio at AACR 2024
Arpeggio presented two exciting posters sharing updates on our GPX4 inhibitor and announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.
